Reproxalap ‐ A Novel Treatment Option for Allergic Conjunctivitis – A Comprehensive Narrative Review

ABSTRACT Background and Aims Allergic conjunctivitis is a prevalent, immune‐mediated hypersensitivity disorder of the ocular surface affecting 10%–20% of the global population. Current therapeutic options, while effective to some extent, are often limited by side effects and inconsistent efficacy. Despite its widespread impact, allergic conjunctivitis receives comparatively less clinical attention than other chronic allergic conditions. This review aims to assess the therapeutic potential and clinical efficacy of Reproxalap, a novel ophthalmic solution targeting reactive aldehyde species (RASP), for the treatment of allergic conjunctivitis. Methods A narrative review was conducted analyzing the pharmacological profile of Reproxalap and its clinical performance in phase 2 and phase 3 clinical trials. These trials evaluated the drug's safety, tolerability, and efficacy based on symptom relief, particularly ocular itching and inflammation. Results Reproxalap demonstrated early‐onset and broad‐spectrum anti‐inflammatory activity through RASP inhibition. By trapping free aldehydes and modulating inflammatory mediators like cytokines and chemokines, it significantly reduced ocular inflammation. Clinical trial data indicated statistically significant improvement in itching scores and sustained symptom relief in patients with allergic conjunctivitis. The drug also showed a favorable safety profile, with minimal adverse events reported. Conclusion Reproxalap represents a first‐in‐class RASP inhibitor with promising efficacy and safety for the treatment of allergic conjunctivitis. Its unique mechanism of action and encouraging clinical trial outcomes support its potential as a valuable therapeutic alternative that may improve patient outcomes and could also be applicable in other inflammatory ocular conditions.